Genistein (GEN) has recently generated considerable interest as a pote
ntial agent for the prevention and treatment of cancer. The present in
vestigation was undertaken to determine if the concentrations of drug
shown to inhibit the growth of human tumor cell lines by 50% in vitro
(IC50=2-27 mu g/ml) can be achieved and sustained systemically in mice
. We found that GEN plasma levels decreased biexponetially from 64 mu
g/ml to 0.55 mu g/ml during the initial 40 min after i.v. injection of
a 52 mg/kg dose. Mean half-lives of the two initial disposition phase
s were 2.5+/-0.4 min and 7.1+/-1.1 min in mice treated with doses of 9
-52 mg/kg. Plasma profiles of i.v. GEN exhibited a prominent secondary
peak near 78 min followed by a terminal decay phase with a 39.5+/-16.
8 min half-life. Although these features are suggestive of enterohepat
ic cycling, the mean apparent total plasma clearance of GEN (66.5+/-7.
3 ml/min/kg) was nevertheless similar to hepatic blood flow. The syste
mic availability of GEN from a 180 mg/kg p.o. dose, which afforded 1.1
mu g/ml peak plasma concentration, was only 12%. Thus, bolus i.v. and
p.o. administration of GEN failed to either achieve or adequately sus
tain plasma levels of the drug within the target range established by
in vitro antitumor studies. Plasma levels resulting from i.p. injectio
n of a 185 mg/kg dose were 5-times greater on average than achieved by
the p.o. route. While the plasma concentration exceeded the IC50 valu
es for the majority of human cancer cell lines responsive to GEN for o
nly a short period of time, drug levels remained above 2 mu g/ml, the
IC50 of the most sensitive cell lines, for 4 h. Extrapolation from the
single dose study suggests that repetitive i.p. injection of at least
200 mg/kg GEN every 8 h will afford continuous systemic exposure to p
otentially cytostatic concentrations of the drug against these cell li
nes. This information should facilitate efforts to assess the effectiv
eness of GEN in appropriate in vivo tumor models.